bpc 157 carcinogenesis study BPC-157: Tendon Repair and More BPC 157 Benefits: Heal &
Description
Thanks, Saba
Initial clinical trials only tested a gap of less than six months between doses, but unexpected popularity and resulting shortages caused further testing to validate wider spacing of the two doses
So they provided some nice graphics and figures in the study where they just made it really organized, like this is low, this is moderate, this is high
LVs have a better safety profile than -RVs in hematopoietic cells [156] and are less genotoxic than -RVs in transplanted mice [157], [158], due to the differential DNA targeting of the two vectors [159]
Ross, R
